AUTHOR INDEX

(P = Proceedings)

AARTS, L.P.H.J. *see* KNIBBE, C.A.J.
ABDELHAMEED, M.H. *see* JUNG, D.
ABDULJAWAD, K.A.J. *see* TAVERNOR, S.J.
ABDUL-MANAP, R., WRIGHT, C.E., ROSTAMI-HODJEGAN, A., MELLER, S., LENNARD, M.S., MORICE, A.H. & TUCKER, G.T. Cytochrome P450 2D6 (CYP2D6) activity in relation to the antitussive effect of dextromethorphan, 586P
ADACHI, T. *see* FUJITA, J.
AFFRIME, M.B. *see* ANJUM, S.
AKASAKA, I. *see* OHTAWA, M.
ALLAIN, H. *see* PATAT, A.
ALMOND, S. *see* FERNER, R.E.
ANDREWS, C. *see* SEYMOUR, R.A.
ANHOJ, J., BISGAARD, H. & LIPWORTH, B.J. Effect of electrostatic charge in plastic spacers of the lung delivery of HFA-salbutamol in children, 333
ANJUM, S., SWAN, S.K., LAMBRECHT, L.J., RADWANSKI, E., CUTLER, D.L., AFFRIME, M.B. & HALSTENSON, C.E. Pharmacokinetics of flutamide in patients with renal insufficiency, 43
ANTON, C. *see* FERNER, R.E.
ANTTILA, M. *see* LAINE, K.
ANUMBA, D. *see* MAJMUDAR, N.G.
APPEL-DINGEMANSE, S., LEMARECHAL, M.-O., KUMLE, A., HUBERT, M. & LEGANGNEUX, E. Integrated modelling of the clinical pharmacokinetics of SDZ HTF 919, a novel selective 5-HT_4 receptor agonist, following oral and intravenous administration, 483
ARCIDIACONO, M.M. *see* SCAGLIONE, F.
ARNOLD, J.M.O. *see* LAMBERT, M.L.
ASHBY, J. *see* ELSBY, R.
ASSANG, C. *see* PRUEKSARITANONT, T.
ASWANIA, O.A., CORLETT, S.A. & CHRYSTYN, H. Relative bioavailability of sodium cromoglycate to the lung following inhalation, using urinary excretion, 613
AZAZ-LIVSHITS, T. *see* TEGEDER, I.
AZUMA, J. *see* FUKUDA, T.

BACK, D.J. *see* EAGLING, V.A.
BACK, D.J. *see* PROFIT, L.
BACK, D. *see* TUCKER, G.T.
BAILLIE, T.A. *see* PRUEKSARITANONT, T.
BAKKER, A. *see* KLUNGEL, O.H.
BALD, M. *see* KREMENS, B.
BANKEN, L. *see* WEBER, C.
BANNWARTH, B., LAGRANGE, F., PÉHOURCQ, F., LLANAS, B. & DEMARQUEZ, J.L. (S)-ketoprofen accumulation in premature neonates with renal failure who were exposed to the racemate during pregnancy, 459
BARCLAY, M.L. *see* BEGG, E.J.
BARNES, J. & MILLS, S. A reply, 229
BARRY, P.W. & O'CALLAGHAN, C. A comparative analysis of the particle size output of beclomethasone diproprionate, salmeterol xinafoate and fluticasone propionate metered dose inhalers used with the babyhaler, volumatic and aerochamber spacer devices, 357
BATEMAN, D.N. *see* CAMPBELL, M.
BAUER, S. *see* SACHSE, C.
BAYLISS, M.K. *see* CARLILE, D.J.
BEER, M.S. *see* RAZZAQUE, Z.
BEERAHEE, A. *see* TAYLOR, A.
BÉGAUD, B. *see* PIERFITTE, C.
BEGG, E.J. *see* KIRKPATRICK, C.M.J.
BEGG, E.J. *see* WILKINSON, T.J.
BEGG, E.J., BARCLAY, M.L. & KIRKPATRICK, C.J.M. The therapeutic monitoring of antimicrobial agents, 23
BEGGS, P.W., CLARK, D.W.J., WILLIAMS, S.M. & COULTER, D. M. A comparison of the use, effectiveness and safety of bezafibrate, gemfibrozil and simvastatin in normal practice using the New Zealand Intensive Medicines Monitoring Programme (IMMP), 99
BEGLINGER, C. *see* RITZ, M.A.
BEIJNEN, J.H. *see* HUITEMA, A.D.R.
BEIJNEN, J.H. *see* MALINGRE, M.M.
BEIJNEN, J.H. *see* MEERUM TER WOGT, J.M.
BEIJNEN, J.H. *see* VAN HEESWIJK, R.P.G.
BERGMAN, U. *see* OLESEN, C.
BERTILSSON, L. *see* BRYNNE, N.
BIBER, A. *see* VAN LIER, J.J.
BIRCH, D. & KAMALI, F. Alcohol and illicit drug use in medical students and junior doctors at Newcastle University: a longitudinal study, 582P
BIRCH, D. & KAMALI, F. Job satisfaction and stress in pre-registration house officers in the north east of England, 600P
BIRNBOECK, H. *see* WEBER, C.
BIRNIE, D.H. *see* SWAN, L.
BISGAARD, H. *see* ANHOJ, J.
BLASCHKE, T.F. *see* CHALON, S.
BLASCHKE, T.F. *see* TANGPHAO, O.
BOCHNER, F. *see* FOSTER, D.J.R.
BOEIJINGA, J.K. *see* VAN DEN ENDE, R.
BONZEL, K.-E. *see* BUSCHER, R.
BOOCOCK, D.J., MAGGS, J.L., BROWN, K., WHITE, I.N.H. & PARK, B.K. Glucuronylation of α-hydroxytamoxifen: a deactivation pathway in humans?, 578P
BOOMSMA, F. *see* TEISMAN, A.C.H.
BOREA, P.A. *see* VARANI, K.
BORGÅ, O. *see* THORSSON, L.
BOSCHMA, M.U.S. *see* MEERUM TER WOGT, J.M.
BÖTTIGER, Y. *see* BRYNNE, N.
BOULTON, D.W., DAKERS, J.M., FAWCETT, J.P. & FIDDES, T.M. Transplacental distribution of labetalol stereoisomers at delivery, 573
BRADSHAW, C.M. *see* TAVERNOR, S.J.
BRECKENRIDGE, A.M. Clinical pharmacology and drug regulation, 11
BRENDEL, E. *see* KREMENS, B.
BRESSERS, H.P.H.M. *see* LANSDORP, D.
BRETELER, M.M. *see* KLUNGEL, O.H.
BRIDGE, S. *see* GROSS, A.S.
BRINKMAN, K. *see* TER HOFSTEDE, H.J.M.
BROCKMÖLLER, J. *see* SACHSE, C.
BRODDE, O.E. *see* SCHÄFERS, R.F.
BROWN, K. *see* BOOCOCK, D.J.
BRUNE, K. *see* TEGEDER, I.
BRYNNE, N., BÖTTIGER, Y., HALLÉN, B. & BERTILSSON, L. Tolterodine does not affect the human *in vivo* metabolism of the probe drugs caffeine, debrisoquine and omeprazole, 145
BUJO, H. *see* KOBAYASHI, J.
BURGER, D.M. *see* TER HOFSTEDE, H.J.M.
BURGGRAAF, J. *see* FAAIJ, R.A.
BURGGRAAF, J., VAN HAARST, A.D., FOCKENS, P., SCHOEMAKER, H. C., KRAUWINKEL, W.J.J. & COHEN, A.F. The gastrointestinal passage and release of beclomethasone dipropionate from oral delivery systems in ileostomy volunteers, 474P
BURRONI, D. *see* REGAZZI, M.B.
BUSCHER, R., KEFFEL, S., MICHEL-REHER, M., BONZEL, K.-E., WINGEN, A.-M., HOYER, P.F. & MICHEL, M.C. Platelet adenylyl cyclase signalling in children undergoing haemodialysis treatment, 576P

© 1999 Blackwell Science Ltd

CAI, M.H. *see* CAI, W.M.
CAI, W.M., CHEN, B., CAI, M.H., CHEN, Y. & ZHANG, Y.D. The influence of CYP2D6 activity on the kinetics of propafenone enantiomers in Chinese subjects, 553
CAIAZZA, A. *see* VARANI, K.
CALLOW, I.D. *see* LAMBERT, M.L.
CALVERT, R.T. Clinical pharmacy — a hospital perspective, 231
CAMPBELL, M., YOUNG, P.I., BATEMAN, D.N., SMITH, J.M. & THOMAS, S.H.L. The use of atypical antipsychotics in the management of schizophrenia, 13
CANAL, P. *see* CHATELUT, E.
CAPLAIN, H. *see* CHAUFOUR, S.
CARLILE, D.J., HAKOOZ, N., BAYLISS, M.K. & HOUSTON, J. B. Microsomal prediction of *in vivo* clearance of CYP2C9 substrates in humans, 625
CHALON, S. *see* TANGPHAO, O.
CHALON, S., TEJURA, B., MORENO Jnr, H., URAE, A., BLASCHKE, T.F. & HOFFMAN, B.B. Role of nitric oxide in isoprenaline and sodium nitroprusside-induced relaxation in human hand veins, 91
CHAN, A. *see* LEE, H.S.
CHATELUT, E., ROSTAING, L., GRÉGOIRE, N., PAYEN, J.-L., PUJOL, A., IZOPET, J., HOUIN, G. & CANAL, P. A pharmacokinetic model for alpha interferon administered subcutaneously, 365
CHAUFOUR, S. *see* PATAT, A.
CHAUFOUR, S., CAPLAIN, H., L'HÉRITIER, C., LILIENTHAL, N., DESCHAMPS, C., DUBRUC, C. & ROSENZWEIG, P. Study of cardiac repolarization in healthy volunteers performed with mizolastine, a new H_1-receptor antagonist, 515
CHAUMET-RIFFAUD, P. *see* TENNEZÉ, L.
CHEE, K.T. *see* LEE, H.S.
CHEN, B. *see* CAI, W.M.
CHEN, Y. *see* CAI, W.M.
CHEUNG, B.M.Y. & LAU, C.-P. Fosinopril reduces left ventricular mass in untreated hypertensive patients: a controlled trial, 179
CHONG, S.A. *see* LEE, H.S.
CHOO, C.H. *see* LEE, H.S.
CHRYSTYN, H. *see* ASWANIA, O.A.
CHRYSTYN, H. *see* HAWKSWORTH, G.M.
CITERONE, D. *see* TAYLOR, A.
CLARK, D.W.J. *see* BEGGS, P.W.
CLEOPHAS, T.J. *see* VAN DER VRING, J.A.
CNATTINGIUS, S. *see* NORDMARK, A.
COCCHI, L. *see* REGAZZI, M.B.
COHEN, A.F. *see* BURGGRAAF, J.
COHEN, A.F. *see* FAAIJ, R.A.
COHEN, A.F. *see* VAN DEN ENDE, R.
CONROY, J.A. *see* LEE, Y.
COOKE, T. *see* WEN, Y.
CORLETT, A.J. *see* HAWKSWORTH, G.M.
CORLETT, S.A. *see* ASWANIA, O.A.
COULTER, D.M. *see* BEGGS, P.W.
COUR, V. *see* HOUSTON, A.C.
CREMERS, S.C.L.M., SPARIDANS, R.W., DEN HARTIGH, J., HAMDY, N.A.T., VERMEIJ, P. & PAPAPOULOS, S.E. Pharmacokinetics of intravenous pamidronate in patients with normal rate of bone turnover, 464P
CRIEGEE-RIECK, M. *see* TEGEDER, I.
CUTLER, D.L. *see* ANJUM, S.
CZYBORRA, P. *see* KREMENS, B.

DAKERS, J.M. *see* BOULTON, D.W.
DAL-RÉ, R. *see* PARDO, A.
DANHOF, M. KNIBBE, C.A.J.
DANIËLS, M.C.G. *see* VAN DER VRING, J.A.F.M.
DANIELS, M.C. *see* VAN DER VRING, J.A.
DANSER, A.H.J., OSTEROP, A.P.R.M., DEINUM, J. & SCHALEKAMP, M.A.D.H. No difference in local angiotensin I to II conversion in subjects of different angiotensin-converting enzyme genotypes, 471P
DATTANI, R.G., HARRY, F., HUTCHINGS, A.D. & ROUTLEDGE, P. A. The effects of acute ethanol intake on isoniazid pharmacokinetics, 591P
DAUL, A.E. *see* SCHÄFERS, R.F.
DAURAT, V. *see* TENNEZÉ, L.
DAVID, O. & JOHNSTON, A. Predicting cyclosporin area under the concentration-time curve is better achieved using artificial neural networks than linear regression, 589P
DAVY, M. *see* TAYLOR, A.
DE ABAJO, F.J. & RODRÍGUEZ, L.A.G. Risk of ventricular arrhythmias associated with nonsedating antihistamine drugs, 307
DE BEUKELAAR, F. *see* ROON, K.I.
DE BOER, A. *see* KLUNGEL, O.H.
DE BOER, A. *see* VAN DE VIJVER
DE BRUIJN, E.A. *see* VAN DER HEYDEN, S.A.M.
DE GRAEFF, P.A. *see* WIERINGA, N.F.
DE HOON, J.N.J.M., STRUIJKER, H.A.J. & VAN BORTEL, L.M.A.B. Different vascular effects of dihydroergotaminie on large arteries and resistance vessels in man, 470P
DE KAM, P.J. *see* TEISMAN, A.C.H.
DE LEIJ, L.F.M.H. *see* TAMMINGA, W.J.
DE MEY, C. *see* SCHÄFERS, R.F.
DE SMET, M. *see* LEE, Y.
DE ZEEUW, D. *see* TEISMAN, A.C.H.
DE ZEEUW, R.A. *see* TAMMINGA, W.J.
DEINUM, J. *see* DANSER, A.H.J.
DEKENS-KONTER, J.A.M. *see* LANSDORP, D.
DEL CASTILLO, S. *see* PARDO, A.
DEMARQUEZ, J.L. *see* BANNWARTH, B.
DEMARTINI, G. *see* SCAGLIONE, F.
DEN HARTIGH, J. *see* CREMERS, S.C.L.M.
DERBY, L.E., MYERS, M.W. & JICK, H. Use of dexfenfluramine, fenfluramine and phentermine and the risk of stroke, 565
DERENDORF, H. *see* MAYER, B.X.
DESCHAMPS, C. *see* CHAUFOUR, S.
DILGER, K., ECKHARDT, K., HOFMANN, U., KUCHER, K., MIKUS, G. & EICHELBAUM, M. Chronopharmacology of intravenous and oral modified release verapamil, 413
disease, 579P
DIXON, R. *see* MINTON, N.
DOLLERY, C.T. Drug discovery and development in the molecular era, 5
DORMANN, H. *see* TEGEDER, I.
DORR, A. *see* JUNG, D.
DOYLE, M.C.T. *see* WEN, Y.
DREWE, J. *see* RITZ, M.A.
DUBRUC, C. *see* CHAUFOUR, S.
DUCHIN, K. *see* MALINGRE, M.M.
DUFFULL, S.B. *see* KIRKPATRICK, C.M.J.
DUGNANI, S. *see* SCAGLIONE, F.

EAGLING, V.A. *see* PROFIT, L.
EAGLING, V.A., PROFIT, L. & BACK, D.J. The effect of grapefruit juice constituents on the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of saquinavir, 593P
ECKHARDT, K. *see* DILGER, K.
EDSBÄCKER, S. *see* THORSSON, L.
EGBERTS, A.C.G. *see* VAN PUIJENBROEK, E.P.
EICHELBAUM, M. *see* DILGER, K.
EICHLER, H.-G. *see* MAYER, B.X.
ELSBY, R., MAGGS, J.L., ASHBY, J. & PARK, B.K. A possible role for metabolism in modulating the oestrogenic activity of xenoestrogens measured by the rodent uterotrophic assay, 589P
ERICSSON, H., FAKT, C., JOLIN-MELLGÅRD, A., NORDLANDER, M., SOHTELL, L., SUNZEL, M. & REGÅRDH, C.G. Clinical and pharmacokinetic results with a new ultrashort-acting calcium antagonist, clevidipine, following

gradually increasing intravenous doses to healthy volunteers, 531
EVANS, J.M.M. & MACDONALD, T.M. Record-linkage for pharmacovigilance in Scotland, 105

FAAIJ, R.A., SRIVASTAVA, N., VAN GRIENSVEN, J.M. TH., SCHOEMAKER, R.C., KLUFT, C., BURGGRAAF, J. & COHEN, A.F. The oral bioavailability of pentosan polysulphate sodium (PPS) in healthy volunteers, 473P
FAKT, C. *see* ERICSSON, H.
FAUSET, A., WILSON, G., OTTERNESS, D., VORA, A. & LENNARD, L. Pharmacogenetics of thiopurine methyltransferase: genotype *vs* phenotype, 597P
FAWCETT, J.P. *see* BOULTON, D.W.
FEELY, J. *see* HENNESSY, M.
FEELY, J. *see* MAHMUD, A.
FEELY, J. *see* WEN, Y.
FEELY, J. *see* WILLIAMS, D.
FEELY, J., HENNESSY, M., WILLIAMS, D. & SCOTT, K. Inhibition of debrisoquine hydroxylation by tramadol, 591P
FENG, Q.P. *see* LAMBERT, M.L.
FERNÁNDEZ-PAVÓN, A. *see* PARDO, A.
FERNER, R.E., HUTCHINGS, A., ANTON, C., ALMOND, S., JONES, A. & ROUTLEDGE, P.A. The origin of errors in dosage: acetylcysteine as a paradigm, 581P
FERRARI, M.D. *see* ROON, K.I.
FERRER, J.M. *see* MARTÍNEZ-MIR, I.
FERRO, C.J. *see* SMITH, P.J.W.
FIDDES, T.M. *see* BOULTON, D.W.
FITZPATRICK, K. *see* TAYLOR, A.
FLORES, N.A. *see* SHERIDAN, D.J.
FOCKENS, P. *see* BURGGRAAF, J.
FOKUHL, B. *see* SCHÄFERS, R.F.
FORD, G.A. *see* JEENAPONGSA, R.
FORD, G.A. *see* MAJMUDAR, N.G.
FORSYTH, J. *see* ROSTAMI-HODJEGAN, A.
FORSYTH, J., GRUNEWALD, R.A., LENNARD, M.S., ROSTAMI-HODJEGAN, A., SAGAR, H.J. & TUCKER, G.T. Altered caffeine metabolism in patients with Parkinson's disease, 579P
FOSTER, D.J.R., SOMOGYI, A.A.& BOCHNER, F.METHADONE *N*-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4, 403
FRAME, J. *see* SEYMOUR, R.A.
FRASCHINI, F. *see* SCAGLIONE, F.
FREY, F.J. *see* PFISTER, M.
FRÖLICH, M. *see* JANSSEN, Y.J.H.
FUJIMOTO, S. *see* FUJITA, J.
FUJIMURA, A. *see* HARADA, K.
FUJITA, J., TSUDA, K., TAKEDA, T., YU, L., FUJIMOTO, S., KAJIKAWA, M., NISHIMURA, M., MIZUNO, N., HAMAMOTO, Y., MUKAI, E., ADACHI, T. & SEINO, Y. Nisoldipine improves the impaired erythrocyte deformability correlating with elevated intracellular free calcium-ion concentration and poor glycaemic control in NIDDM, 499
FUKUDA, T., YAMAMOTO, I., NISHIDA, Y., ZHOU, Q., OHNO, M., TAKADA, K. & AZUMA, J. Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers, 450
FUNCK-BRENTANO, C. *see* ROSTAMI-HODJEGAN, A.
FUNCK-BRENTANO, C. *see* TENNEZÉ, L.

GANDON, J.M. *see* PATAT, A.
GARCIA-LÓPEZ, M. *see* MARTÍNEZ-MIR, I.
GARCÍA-LOSA, M. *see* PARDO, A.
GARCÍA-MÉNDEZ, E. *see* PARDO, A.
GATES, S. & MINERS, J.O. Cytochrome P450 isoform selectivity in human hepatic theobromine metabolism, 299
GEISSLINGER, G. *see* TEGEDER, I.
GEORGE, C. BJCP 25th Anniversary, 3
GÉRARD, N. *see* PANSERAT, S.
GESSI, S. *see* VARANI, K.
GHAHRAMANI P., JACKSON, P.R. & TUCKER, G.T. Fraction of dose of drug converted to a metabolite when both compete for metabolism by the same enzyme, 578P
GHAHRAMANI, P. *see* NICHOLSON, K.
GIACCHINO, R. *see* REGAZZI, M.B.
GIACCONE, G. *see* MEERUM TER WOGT, J.M.
GIANNAKOPOULOS, G. *see* ILIOPOULOU, A.
GIRBES, A.R.J., PATTEN, M.T. & MCCLOSKEY, B.V. The renal and neurohumoral effects of the addition of low-dose dopamine in septic critically ill patients, 471P
GISLESKOG, P.O., HERMANN, D., HAMMARLUND-UDENAES, M. & KARLSSON, M.O. The pharmacokinetic modelling of GI198745 (dutasteride), a compound with parallel linear and nonlinear elimination, 53
GODDARD, J. *see* SPRATT, J.C.S.
GOGGIN, T. *see* WITTKE, B.
GONZALEZ, F.J. *see* TRACY, T.S.
GOUTOU, P. *see* ILIOPOULOU, A.
GRAHAME-SMITH, D.G. How will knowledge of the human genome affect drug therapy?, 7
GRÉGOIRE, N. *see* CHATELUT, E.
GRIFFY, K. *see* JUNG, D.
GROSS, A.S., BRIDGE, S. & SHENFIELD, G.M. Pharmacokinetics of tolbutamide in ethnic Chinese, 151
GROSSMANN, M. *see* TANGPHAO, O.
GRUNEWALD, R.A. *see* FORSYTH, J.
GRUNEWALD, R.A. *see* ROSTAMI-HODJEGAN, A.
GUCHELAAR, H.-J., SCHULTZ, M.J., VAN DER POLL, T. & KOOPMANS, R.P. Pharmacokinetic (PK)-pharmacodynamic (PD) modelling of the inhibition IL-6 and TNF-α production by erythromycin *ex vivo*, 466P
GUPTA, V. *see* VAN AGTMAEL, M.A.

HAHN, E.-G. *see* TEGEDER, I.
HAKOOZ, N. *see* CARLILE, D.J.
HALE, A. *see* RIDHA, B.
HALLÉN, B. *see* BRYNNE, N.
HALSTENSON, C.E. *see* ANJUM, S.
HAMAMOTO, Y. *see* FUJITA, J.
HAMDY, N.A.T. *see* CREMERS, S.C.L.M.
HAMMARLUND-UDENAES, M. *see* GISLESKOG, P.O.
HANRATTY, C.G., SILKE, B. & RIDDELL, J.G. Evaluation of the effect on heart rate variability of a β_2-adrenoceptor agonist and antagonist using non-linear scatterplot and sequence methods, 157
HAQ, I.U. *see* NICHOLSON, K.
HAQ, I.U., MINNIS, R., WALLIS, E.J., PALMER, R., YEO, W.W., JACKSON, P.R. & RAMSAY, L.E. Randomized trial of step-3 diet *vs* simvastatin therapy for reduction in risk of coronary heart disease, 597P
HARADA, K., OHMORI, M., KITOH, Y., SUGIMOTO, K.-I. & FUJIMURA, A. Impaired ß-adrenoceptor mediated venodilation in patients with diabetes mellitus, 427
HARADA, K., YAMAZAKI, S. & FUJIMURA, A. Providing patients with written information helps them to be aware of and report adverse drug reactions?, 228
HARRISON, R.F. *see* WEN, Y.
HARRY, F. *see* DATTANI, R.G.
HARRY, F. *see* RIDHA, B.
HASEGAWA, A. *see* NAKAMURA, H.
HAWKESFORD, J.E. *see* SEYMOUR, R.A.
HAWKSWORTH, G.M., CORLETT, A.J., WRIGHT, D.J. & CHRYSTYN, H. Clinical pharmacy interventions by community pharmacists during the dispensing process, 695

HEALD, M.A. *see* RAZZAQUE, Z.
HELMINEN, A. *see* LAINE, K.
HENDRIKS, M.G.C. *see* VAN DER VRING, J.A.F.M.
HENDRIKS, M.G. *see* VAN DER VRING, J.A.
HENNESSY, M. *see* FEELY, J.
HENNESSY, M., KELLY, M. & FEELY, J. Poor documentation of drug hypersensitivity in hospital records, 596P
HERINGS, R.M.C. *see* SCHILLEVOORT, I.E.R.M.
HERINGS, R.M.C. *see* VAN DE VIJVER
HERMANN, D. *see* GISLESKOG, P.O.
HICKMOTT, H. & KAMALI, F. Effect of racemic and (R)- and (S)-warfarin on carboxylase activity and the vitamin K cycle, 585P
HIGHLEY, M.S. *see* VAN DER HEYDEN, S.A.M.
HIGUCHI, S. *see* KIMURA, M.
HIKITA, M. *see* KOBAYASHI, J.
HILDEBRAND, P. *see* RITZ, M.A.
HILL, C.M. *see* SEYMOUR, R.A.
HILL, R.G. *see* RAZZAQUE, Z.
HILLIS, W.S. *see* SWAN, L.
HIROTA, K., ISHIHARA, H., TSUBO, T. & MATSUKI, A. Estimation of the initial distribution volume of glucose by an incremental plasma glucose level at 3 min after i. v. glucose in humans, 361
HOETELMANS, R.M.W. *see* VAN HEESWIJK, R.P.G.
HOFFMAN, B.B. *see* CHALON, S.
HOFFMAN, B.B. *see* TANGPHAO, O.
HOFMANN, U. *see* DILGER, K.
HOFMANN, U. *see* WEBB, J.
HOLT, D.W. *see* JOHNSTON, A.
HOLWERDA, N.J.H. *see* VAN DER VRING, J.A.F.M.
HOLWERDA, N.J. *see* VAN DER VRING, J.A.
HOOD, S. *see* SWAN, L.
HOUIN, G. *see* CHATELUT, E.
HOUSTON, A.C., STEVENS, L.A. & COUR, V. Pharmacokinetics of glycosylated recombinant human granulocyte colony-stimulating factor (lenograstim) in healthy male volunteers, 279
HOUSTON, J.B. *see* CARLILE, D.J.
HOWCROFT, D.J. & JONES, R.W. Actigraphy: a useful tool for studying sleep and behavioural problems in older people in their own environment, 601P
HOYER, P.F. *see* R.BUSCHER
HUBERT, M. *see* APPEL-DINGEMANSE, S.
HUGEN, P.W.H. *see* TER HOFSTEDE, H.J.M.
HUGENHOLTZ, G.W.K. *see* SCHILLEVOORT, I.E.R.M.
HUITEMA, A.D.R., SCHELLENS, J.H.M., KERBUSCH, T., TIBBEN, M.M., RODENHUIS, S. & BEIJNEN, J.H. Modelling of the pharmacokinetics and auto-induction of high-dose cyclophosphamide using NONMEM, 465P
HUIZING, M.T. *see* MEERUM TER WOGT, J.M.
HUNTER, J. *see* JUNG, D.
HUTCHINGS, A.D. *see* DATTANI, R.G.
HUTCHINGS, A. *see* FERNER, R.E.
HUTCHINGS, A. *see* RIDHA, B.
HUUPPONEN, R. *see* LAINE, K.

IEIRI, I. *see* KIMURA, M.
IIMORI, E. *see* KIMURA, M.
ILIOPOULOU, A., GIANNAKOPOULOS, G., GOUTOU, P., PAGOU, H. & STAMATELOPOULOS, S. Visual hallucinations due to radiocontrast media. Report of two cases and review of the literature, 226
ISHIHARA, H. *see* HIROTA, K.
IZOPET, J. *see* CHATELUT, E.

JACKSON, P.R. *see* GHAHRAMANI P.
JACKSON, P.R. *see* HAQ, I.U.
JACKSON, P.R. *see* NICHOLSON, K.
JACKSON, P.R. *see* ROWLAND, K.
JACKSON, P.R. *see* WALLIS, E.J.
JACKSON, P.R. What should a clinical pharmacologist know to start a clinical trial (phase I and II)?, 711
JACQZ-AIGRAIN, E. *see* PANSERAT, S.
JAMALI, F. & KUNZ-DOBER, C.M. Pain-mediated altered absorption and metabolism of ibuprofen: an explanation for decreased serum enantiomer concentration after dental surgery, 391
JANSSEN, Y.J.H., FRÖLICH, M. & ROELFSEMA, F. The absorption profile and availability of a physiological subcutaneously administered dose of recombinant human growth hormone (GH) in adults with GH deficiency, 273
JEENAPONGSA, R., THOMAS, T.H. & FORD, G.A. Role of cytoskeleton and effect of ageing in transmembrane receptor adenylate cyclase signalling in human platelets, 594P
JICK, H. *see* DERBY, L.E.
JOHNSTON, A. & HOLT, D.W. Therapeutic drug monitoring of immunosuppressant drugs, 339
JOHNSTON, A. *see* DAVID, O.
JOLIN-MELLGÅRD, A. *see* ERICSSON, H.
JONES, A. *see* FERNER, R.E.
JONES, R.W. *see* HOWCROFT, D.J.
JONKMAN, J.H.G. *see* TAMMINGA, W.J.
JONKMAN, J.H.G. *see* VAN LIER, J.J.
JUNG, D., ABDELHAMEED, M.H., HUNTER, J., TEITELBAUM, P., DORR, A. & GRIFFY, K. The pharmacokinetics and safety profile of oral ganciclovir in combination with trimethoprim in HIV- and CMV-seropositive patients, 255

KAJIKAWA, M. *see* FUJITA, J.
KAMALI, F. *see* BIRCH, D.
KAMALI, F. *see* HICKMOTT, H.
KAMALI, F. *see* WEBB, J.
KARL, I. *see* SCHÄFERS, R.F.
KARLSSON, M.O. *see* GISLESKOG, P.O.
KARNANI, H. *see* LAINE, K.
KEFFEL, S. *see* R.BUSCHER
KELLY, A. *see* WILLIAMS, D.
KELLY, M. *see* HENNESSY, M.
KERBUSCH, T. *see* HUITEMA, A.D.R.
KEYMEULEN, B. *see* LEE, Y.
KHOO, S.H. *see* VILAR, F.J.
KHOO, Y.M. *see* LEE, H.S.
KIMURA, M. *see* NAKAMURA, H.
KIMURA, M., IEIRI, I., WADA, Y., MAMIYA, K., URAE, A., IIMORI, E., SAKAI, T., OTSUBO, K. & HIGUCHI, S. Reliability of the omeprazole hydroxylation index for CYP2C19 phenotyping: possible effect of age, liver disease and length of therapy, 115
KINGSBURY, M.P. *see* SHERIDAN, D.J.
KINIRONS, M.T., KRIVORUK, Y., WILKINSON, G.R. & WOOD, A.J. J. Effects of ketoconazole on the erythromycin breath test and the dapsone recovery ratio, 223
KIRKPATRICK, C.J.M. *see* BEGG, E.J.
KIRKPATRICK, C.M.J., DUFFULL, S.B. & BEGG, E.J. Pharmacokinetics of gentamicin in 957 patients with varying renal function dosed once daily, 637
KITADA, M. *see* NAKAMURA, H.
KITOH, Y. *see* HARADA, K.
KLESSING, K. *see* VAN LIER, J.J.
KLUFT, C. *see* FAAIJ, R.A.
KLUNGEL, O.H., STRICKER, BH. CH., PAES, A.H.P., SEIDELL, J.C., BAKKER, A., BRETELER, M.M. & DE BOER, A. Excess cerebrovascular disease among hypertensive men and women due to undertreatment of hypertension, 476P
KNIBBE, C.A.J., VOORTMAN, H.-J., AARTS, L.P.H.J., KUKS, P.F.M., LANGE, R., LANGEMEIJER, H.J.M. & DANHOF, M. Pharmacokinetics, induction of anaesthesia and safety characteristics of Propofol 6% SAZN *vs* Propofol 1% SAZN and Diprivan®-10 after bolus injection, 653
KOBAYASHI, J., NAGASHIMA, I., HIKITA, M., BUJO, H., TAKAHASHI, K., OTABE, M.,

© 1999 Blackwell Science Ltd

MORISAKI, N. & SAITO, Y. Effect of troglitazone on plasma lipid metabolism and lipoprotein lipase, 433
KOBAYASHI, S. *see* TATEISHI, T.
KOOPMANS, P.P. *see* TER HOFSTEDE, H.J.M.
KOOPMANS, R.P. *see* GUCHELAAR, H.-J.
KORZEKWA, K.R. *see* TRACY, T.S.
KRAUWINKEL, W.J.J. *see* BURGGRAAF, J.
KREMENS, B. Loss of blood pressure control on withdrawal of fluconazole during nifedipine therapy, 707
KRISHNAMOORTHY, R. *see* PANSERAT, S.
KRISHNASWAMI, S. *see* MAYER, B.X.
KRIVORUK, Y. *see* KINIRONS, M.T.
KROEMER, H.K. *see* ROSTAMI-HODJEGAN, A.
KUCHER, K. *see* DILGER, K.
KUKS, P.F.M. *see* KNIBBE, C.A.J.
KUMAI, T. *see* TATEISHI, T.
KUMLE, A. *see* APPEL-DINGEMANSE, S.
KUNZ-DOBER, C.M. *see* JAMALI, F.
KUTIKOVA, L. *see* SCHILLEVOORT, I.E.R.M.

L'HÉRITIER, C. *see* CHAUFOUR, S.
LABINJOH, C. *see* SPRATT, J.C.S.
LAGNAOUI, R. *see* PIERFITTE, C.
LAGRANGE, F. *see* BANNWARTH, B.
LAHLOU, N. *see* RITZ, M.A.
LAINE, K., ANTTILA, M., HELMINEN, A., KARNANI, H. & HUUPPONEN, R. Dose linearity study of selegiline pharmacokinetics after oral administration: evidence for strong drug interaction with female sex steroids, 249
LAMBERT, M.L., CALLOW, I.D., FENG, Q.P. & ARNOLD, J.M.O. The effects of age on human venous responsiveness to neuropeptide Y, 83
LAMBRECHT, L.J. *see* ANJUM, S.
LANGE, J.M.A. *see* VAN HEESWIJK, R.P.G.
LANGE, R. *see* KNIBBE, C.A.J.
LANGEMEIJER, H.J.M. *see* KNIBBE, C.A.J.
LANGEWITZ, W. *see* SCHÄCHINGER, H.
LANGLEY, R.W. *see* TAVERNOR, S.J.
LANSDORP, D., BRESSERS, H.P.H.M., DEKENS-KONTER, J.A.M. & MEYBOOM, R.H.B. Potentiation of acenocoumarol during vaginal administration of miconazole, 225
LAU, C.-P. *see* CHEUNG, B.M.Y.
LAZARUS, J.H. *see* RIDHA, B.
LE COZ, F. *see* PATAT, A.
LEARY, A.C. *see* SHIELS, P.
LEE, H.S., TAN, C.H., KHOO, Y.M., CHEE, K.T., WONG, K.E., CHONG, S.A., MAHENDRAN, R., YAP, H.L., LOW, B.L., CHOO, C. H. & CHAN, A. Serum concentrations and clinical effects of risperidone in schizophrenic patients in Singapore — a preliminary report, 460
LEE, Y., CONROY, J.A., STEPANAVAGE, M.E., MENDEL, C.M., SOMERS, G., MCLOUGHLIN, D.A., OLAH, T.V., DE SMET, M., KEYMEULEN, B. & ROGERS, J.D. Pharmacokinetics and tolerability of oral rizatriptan in healthy male and female volunteers, 373
LEGANGNEUX, E. *see* APPEL-DINGEMANSE, S.
LEMARECHAL, M.-O. *see* APPEL-DINGEMANSE, S.
LENFANT, B. *see* PATAT, A.
LENNARD, L. *see* FAUSET, A.
LENNARD, L. Therapeutic drug monitoring of antimetabolic cytotoxic drugs, 131
LENNARD, M.S. *see* ABDUL-MANAP, R.
LENNARD, M.S. *see* FORSYTH, J.
LENNARD, M.S. *see* ROSTAMI-HODJEGAN, A.
LEUFKENS, H.G.M. *see* SCHILLEVOORT, I.E.R.M.
LEUFKENS, H.G.M. *see* VAN PUIJENBROEK, E.P.
LEVY, M. *see* TEGEDER, I.
LILIENTHAL, N. *see* CHAUFOUR, S.
LIM, P.O. *see* SHIELS, P.
LIN, J.H. *see* PRUEKSARITANONT, T.
LIPWORTH, B.J. *see* ANHOJ, J.
LLANAS, B. *see* BANNWARTH, B.
LONGMORE, J. *see* RAZZAQUE, Z.
LOPEZ-GIL, A. *see* TAYLOR, A.
LOW, B.L. *see* LEE, H.S.
LU, P. *see* PRUEKSARITANONT, T.
LUNDGREN, S. *see* NORDMARK, A.

MA, B. *see* PRUEKSARITANONT, T.
MACDONALD, T.M. *see* EVANS, J.M.M.
MACDONALD, T.M. *see* SHIELS, P.
MACFADYEN, R.J., SHIELS, P. & STRUTHERS, A.D. Clinical case studies in heart failure management, 239
MACHIN, S.J. *see* WITTKE, B.
MACKAY, F.J., PEARCE, G.L. & MANN, R.D. Cough and angiotensin II receptor antagonists: cause or confounding?, 111
MACKIE, I.J. *see* WITTKE, B.
MAES, R.A.A. *see* VAN DER HEYDEN, S.A.M.
MAGGS, J.L. *see* BOOCOCK, D.J.
MAGGS, J.L. *see* ELSBY, R.
MAHENDRAN, R. *see* LEE, H.S.
MAHMUD, A. & FEELY, J. Passive smoking increases arterial stiffness in healthy subjects, 575P
MAHMUD, A. & FEELY, J. Reduced vascular stiffness by angiotensin II receptor blockade in uncontrolled hypertension, 586P
MAJMUDAR, N.G., ANUMBA, D., ROBSON, S.C. & FORD, G.A. Contribution of nitric oxide to β_2-adrenoceptor mediated vasodilatation in human forearm arterial vasculature, 173
MALINGRE, M.M., SCHELLENS, J.H.M., DUCHIN, K., ROSING, H. & BEIJNEN, J.H. Oral paclitaxel in a twice daily dose regimen, 463P
MAMIYA, K. *see* KIMURA, M.
MANN, R.D. *see* MACKAY, F.J.
MARTÍNEZ-MIR, I. GARCÍA-LÓPEZ, M. PALOP, V. FERRER, J. M. RUBIO, E. & MORALES-OLIVAS, F.J. A prospective study of adverse drug reactions in hospitalized children, 681
MASERATI, R. *see* REGAZZI, M.B.
MASKELL, L. *see* RAZZAQUE, Z.
MASUDA, N. *see* OHTAWA, M.
MATHIEU, H. *see* PANSERAT, S.
MATSUKI, A. *see* HIROTA, K.
MATTILA, M.J. & VANAKOSKI, J. Simulated driving in light and dark conditions: elderly subjects, alcohol and diazepam, 600P
MAYER, B.X., MENSIK, C., KRISHNASWAMI, S., DERENDORF, H., EICHLER, H.-G., SCHMETTERER, L. & WOLZT, M. Pharmacokinetic-pharmacodynamic profile of systemic nitric oxide-synthase inhibition with L-NMMA in humans, 539
MAZOIT, J.X. & SAMII, K. Binding of propofol to blood components: implications for pharmacokinetics and for pharmacodynamics, 35
MCCANN, G.P. *see* SWAN, L.
MCCLOSKEY, B.V. *see* GIRBES, A.R.J.
MCINNES, G. *see* TUCKER, G.T.
MCLOUGHLIN, D.A. *see* LEE, Y.
MCMAHON, A.D. *see* SHIELS, P.
MCQUEEN, D.S. *see* SMITH, P.J.W.
MEENHORST, P.L. *see* VAN HEESWIJK, R.P.G.
MEERUM TER WOGT, J.M., TELLINGEN, O.V., NANNAN PANDAY, V. R., HUIZING, M.T., TEN BOKKEL HUININK, W.W., BOSCHMA, M.U. S., GIACCONE, G., VEENHOF, C.H.N. & BEIJNEN, J.H. Pharmacokinetics of Cremophor EL in a phase 1 study with paclitaxel (Taxol) and carboplatin in patients with non-small cell lung cancer, 463P
MELLER, S. *see* ABDUL-MANAP, R.
MENDEL, C.M. *see* LEE, Y.

MENG, Y. *see* PRUEKSARITANONT, T.
MENNICKE, K. *see* SCHÄFERS, R.F.
MENSIK, C. *see* MAYER, B.X.
MEYBOOM, R.H.B. *see* LANSDORP, D.
MEYBOOM, R.H.B. *see* VAN PUIJENBROEK, E.P.
MICHEL, M.C. *see* BUSCHER, R.
MICHEL, M.C. *see* KREMENS, B.
MICHEL, M.C. *see* SCHÄFERS, R.F.
MICHEL-REHER, M. *see* R.BUSCHER
MIKUS, G. *see* DILGER, K.
MIKUS, G. *see* WEBB, J.
MILLS, S. *see* BARNES, J.
MINERS, J.O. *see* GATES, S.
MINNIS, R. *see* HAQ, I.U.
MINTON, N., DIXON, R., WILD, M. & WARRANDER, A. Drug interaction studies and metabolic enzyme characterization with zolmitriptan ('Zomig'), 588P
MIZUNO, N. *see* FUJITA, J.
MOORE, N.D. *see* PIERFITTE, C.
MORALES-OLIVAS, F.J. *see* MARTÍNEZ-MIR, I.
MORENO JNR, H. *see* CHALON, S.
MORICE, A.H. *see* ABDUL-MANAP, R.
MORISAKI, N. *see* KOBAYASHI, J.
MORIYASU, M. *see* OHTAWA, M.
MUIR, D.F. *see* SWAN, L.
MUKAI, E. *see* FUJITA, J.
MULDER, J.W. *see* VAN HEESWIJK, R.P.G.
MÜLLER, B.U. *see* SCHÄCHINGER, H.
MURRAY, V. *see* SHAW, D.
MUTH-SELBACH, U. *see* TEGEDER, I.
MYERS, M.W. *see* DERBY, L.E.

NAGASHIMA, I. *see* KOBAYASHI, J.
NAKAMURA, H., HASEGAWA, A., KIMURA, M., YAMAGATA, S.-I., NAKASA, H., OSADA, H., SEKIYA, S., OHMORI, S. & KITADA, M. Comparison of urinary 6β-hydroxycortisol/cortisol ratio between neonates and their mothers, 31
NAKASA, H. *see* NAKAMURA, H.
NAKASHIMA, A. *see* OHTAWA, M.
NAKURA, H. *see* TATEISHI, T.
NANNAN PANDAY, V.R. *see* MEERUM TER WOGT, J.M.
NAVE, S. *see* WEBER, C.
NEUMANN, F. *see* TEGEDER, I.
NICHOLSON, K., RAMSAY, L.E., HAQ, I.U., WALLIS, E.J., GHAHRAMANI, P., JACKSON, P.R. & YEO, W.W. Factors affecting the acceptance of drug therapy to prevent myocardial infarction, 580P
NIELSEN, G.L. *see* OLESEN, C.
NIEMINEN, M.S. *see* SINISALO, J.
NISHIDA, Y. *see* FUKUDA, T.
NISHIMURA, M. *see* FUJITA, J.
NORDLANDER, M. *see* ERICSSON, H.
NORDMARK, A., LUNDGREN, S., CNATTINGIUS, S. & RANE, A. Dietary caffeine as a probe agent for assessment of cytochrome P4501A2 activity in random urine samples, 397
NORRIS, L.A. *see* WEN, Y.

O'CALLAGHAN, C. *see* BARRY, P.W.
OCHIAI, K. *see* OHTAWA, M.
OELKERS, R. *see* TEGEDER, I.
OHMORI, M. *see* HARADA, K.
OHMORI, S. *see* NAKAMURA, H.
OHNO, M. *see* FUKUDA, T.
OHTAWA, M., MASUDA, N., AKASAKA, I., NAKASHIMA, A., OCHIAI, K. & MORIYASU, M. Cellular uptake of fluvastatin, an inhibitor of HMG-CoA reductase, by rat cultured hepatocytes and human aortic endothelial cells, 383
OLAH, T.V. *see* LEE, Y.
OLESEN, C., STEFFENSEN, F.H., SORENSEN, H.T., NIELSEN, G. L., OLSEN, J. & BERGMAN, U. Low use of long-term hormone replacement therapy in Denmark, 323
OLSEN, J. *see* OLESEN, C.
OOSTERHUIS, B. *see* TAMMINGA, W.J.
OOSTERHUIS, B. *see* VAN LIER, J.J.
OSADA, H. *see* NAKAMURA, H.
OSTEROP, A.P.R.M. *see* DANSER, A.H.J.
OTABE, M. *see* KOBAYASHI, J.
OTSUBO, K. *see* KIMURA, M.
OTTERNESS, D. *see* FAUSET, A.

PAES, A.H.P. *see* KLUNGEL, O.H.
PAGOU, H. *see* ILIOPOULOU, A.
PAJUNEN, P. *see* SINISALO, J.
PALMER, R. *see* HAQ, I.U.
PALOP, V. *see* MARTÍNEZ-MIR, I.
PANSERAT, S., SICA, L., GÉRARD, N., MATHIEU, H., JACQZ-AIGRAIN, E. & KRISHNAMOORTHY, R. CYP2D6 polymorphism in a Gabonese population: contribution of the *CYP2D6*2* and *CYP2D6*17* alleles to the high prevalence of the intermediate metabolic phenotype, 121
PAPAPOULOS, S.E. *see* CREMERS, S.C.L.M.
PARDO, A., GARCÍA-LOSA, M., FERNÁNDEZ-PAVÓN, A., DEL CASTILLO, S., PASCUAL-GARCÍA, T., GARCÍA-MÉNDEZ, E. & DAL-RÉ, R. A placebo-controlled study of interaction between nabumetone and acenocoumarol, 441
PARK, B.K. *see* BOOCOCK, D.J.
PARK, B.K. *see* ELSBY, R.
PASCUAL-GARCÍA, T. *see* PARDO, A.
PATAT, A., CHAUFOUR, S., GANDON, J.M., ALLAIN, H. & ROSENZWEIG, P. Safety and pharmacodynamics of single ascending doses of SL34.0026, a new reversible and selective MAO-B inhibitor in healthy subjects, 584P
PATAT, A., SULTAN, E., RICHARD, A.S., LENFANT, B., LE COZ, F. & GANDON, J.M. Pharmacokinetics of milameline in patients with impaired liver function, 590P
PATEL, N. *see* SPRATT, J.C.S.
PATTEN, M.T. *see* GIRBES, A.R.J.
PAYEN, J.-L. *see* CHATELUT, E.
PEARCE, G.L. *see* MACKAY, F.J.
PEETERS, P.A.M. *see* VAN LIER, J.J.
PÉHOURCQ, F. *see* BANNWARTH, B.
PFISTER, M., SCHAEDELI F., FREY, F.J. & UEHLINGER D.E. Pharmacokinetics and haemodynamics of candesartan cilexetil in hypertensive patients on regular haemodialysis, 645
PHILIPP, T. *see* SCHÄFERS, R.F.
PICKARD, J.D. *see* RAZZAQUE, Z.
PIERFITTE, C., BÉGAUD, B., LAGNAOUI, R. & MOORE, N.D. Is reporting rate a good predictor of risks associated with drugs?, 329
PINTO, Y.M. *see* TEISMAN, A.C.H.
PINTUCCI, J.P. *see* SCAGLIONE, F.
PORSIUS, A.J. *see* VAN DE VIJVER
PORTALUPPI, F. *see* VARANI, K.
PROFIT, L. *see* EAGLING, V.A.
PROFIT, L., EAGLING, V.A. & BACK, D.J. The effect of P-glycoprotein on saquinavir absorption in Caco-2 cells, 594P
PRUEKSARITANONT, T., MA, B., TANG, C., MENG, Y., ASSANG, C., LU, P., REIDER, P.J., LIN, J.H. & BAILLIE, T.A. Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: An *in vitro* investigation with human liver preparations, 291
PUJOL, A. *see* CHATELUT, E.

RADWANSKI, E. *see* ANJUM, S.
RAMSAY, L.E. *see* HAQ, I.U.
RAMSAY, L.E. *see* NICHOLSON, K.
RAMSAY, L.E. *see* ROWLAND, K.
RAMSAY, L.E. *see* WALLIS, E.J.
RANE, A. *see* NORDMARK, A.
RANKIN, A.J. *see* SPRATT, J.C.S.
RASTELLI, G. *see* VARANI, K.
RAVNSKOV, U. Glomerular, tubular and interstitial nephritis associated with non-steroidal antiinflammatory drugs. Evidence of a common mechanism, 203
RAZZAQUE, Z., HEALD, M.A., PICKARD, J.D., MASKELL, L., BEER, M.S., HILL, R.G. & LONGMORE, J. Vasconstriction in human isolated middle meningeal arteries: determining the contribution of

5-HT_{1B}-and 5-HT_{1L}-receptor activation, 75
REEUWIJK, H.J.E.M. *see* VAN DER HEYDEN, S.A.M.
REGÅRDH, C.G. *see* ERICSSON, H.
REGAZZI, M.B., VILLANI, P., MASERATI, R., COCCHI, L., GIACCHINO, R., BURRONI, D. & RETTANI, M. Pharmacokinetic variability and strategy for therapeutic drug monitoring of saquinavir (SQV) in HIV-1 infected individuals, 379
REIDER, P.J. *see* PRUEKSARITANONT, T.
REISS, P. *see* VAN HEESWIJK, R.P.G.
RETTANI, M. *see* REGAZZI, M.B.
RICHARD, A.S. *see* PATAT, A.
RIDDELL, J.G. *see* HANRATTY, C.G.
RIDHA, B., HALE, A., HARRY, F., HUTCHINGS, A., SIM, E., ROUTLEDGE, P.A. & LAZARUS, J.H. Hashimoto's thyroiditis and acetylator status: a comparison of genotype and phenotype, 592P
RITZ, M.A., DREWE, J., ZIEL, A., HILDEBRAND, P., SCHNEIDER, P., LAHLOU, N. & BEGLINGER, C. The effects of vapreotide, a somatostatin analogue, on gastric acidity, gallbladder emptying and hormone release after 1 week of continuous subcutaneous infusion in normal subjects, 195
RITZ, R. *see* SCHÄCHINGER, H.
ROBSON, S.C. *see* MAJMUDAR, N.G.
RODENHUIS, S. *see* HUITEMA, A.D.R.
RODRÍGUEZ, L.A.G. *see* DE ABAJO, F.J.
ROELFSEMA, F. *see* JANSSEN, Y.J.H.
ROGERS, J.D. *see* LEE, Y.
ROON, K.I., SOONS, P.A., UITENDAAL, M.P., DE BEUKELAAR, F. & FERRARI, M.D. Pharmacokinetic profile of alniditan nasal spray during and outside migraine attacks, 285
ROOS, R.A.C. *see* SCHILLEVOORT, I.E.R.M.
ROOS, R.A.C. *see* VAN DE VIJVER
ROOTS, I. *see* SACHSE, C.
ROSENZWEIG, P. *see* CHAUFOUR, S.
ROSENZWEIG, P. *see* PATAT, A.
ROSING, H. *see* MALINGRE, M.M.
ROSTAING, L. *see* CHATELUT, E.
ROSTAMI-HODJEGAN, A. *see* ABDUL-MANAP, R.
ROSTAMI-HODJEGAN, A. *see* FORSYTH, J.
ROSTAMI-HODJEGAN, A., FORSYTH, J., GRUNEWALD, R.A., LENNARD, M.S., SAGAR, H.J. & TUCKER, G.T. The paraxanthine/caffeine ratio in saliva as a marker of CYP1A2 activity, 587P
ROSTAMI-HODJEGAN, A., FUNCK-BRENTANO, C., KROEMER, H.K. & TUCKER, G.T. *In vivo* indices of enzyme activity: the effect of renal impairment on the assessment of CYP2D6 activity, 577P
ROUTLEDGE, P.A. *see* DATTANI, R.G.
ROUTLEDGE, P.A. *see* FERNER, R.E.
ROUTLEDGE, P.A. *see* RIDHA, B.
ROUTLEDGE, P.A. The interface between Clinical and Laboratory Pharmacology, 611
ROWLAND, K., YEO, W.W., JACKSON, P.R. & RAMSAY, L.E. Effect of diltiazem on the cholesterol-lowering response to simvastatin: a CYP3A4-mediated reaction, 598P
RUBIO, E. *see* MARTÍNEZ-MIR, I.

SACHSE, C., BROCKMÖLLER, J., BAUER, S. & ROOTS, I. Functional significance of a C→A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine, 445
SAGAR, H.J. *see* FORSYTH, J.
SAGAR, H.J. *see* ROSTAMI-HODJEGAN, A.
SAINSBURY, R. *see* WILKINSON, T.J.
SAITO, Y. *see* KOBAYASHI, J.
SAKAI, T. *see* KIMURA, M.
SAMII, K. *see* MAZOIT, J.X.
SARIS, W.H.M. *see* SCHIFFELERS, S.L.H.
SCAGLIONE, F., DEMARTINI, G., DUGNANI, S., ARCIDIACONO, M.M., PINTUCCI, J.P. & FRASCHINI, F. Interpretation of middle ear fluid concentrations of antibiotics: comparison between ceftibuten, cefixime and azitromycin, 267
SCHÄCHINGER, H., MÜLLER, B.U., STROBEL, W., LANGEWITZ, W. & RITZ, R. Midazolam effects on prepulse inhibition of the acoustic blink reflex, 421
SCHAEDELI F. *see* PFISTER, M.
SCHÄFERS, R.F., FOKUHL, B., WASMUTH, A., SCHUMACHER, H., TAGUCHI, K., DE MEY, C., PHILIPP, T. & MICHEL, M.C. Differential vascular α_1-adrenoceptor antagonism by tamsulosin and terazosin, 67
SCHÄFERS, R.F., KARL, I., MENNICKE, K., DAUL, A.E., PHILIPP, T. & BRODDE, O.E. Ketotifen and cardiovascular effects of xamoterol following single and chronic dosing in healthy volunteers, 59
SCHALEKAMP, M.A.D.H. *see* DANSER, A.H.J.
SCHELLENS, J.H.M. *see* HUITEMA, A.D.R.
SCHELLENS, J.H.M. *see* MALINGRE, M.M.
SCHELLING, A. *see* VAN DER VRING, J.A.
SCHELLING, A. *see* VAN DER VRING, J.A.F.M.
SCHELLING, A., CLEOPHAS, T.J. & HENDRIKS, M.G. Addition of calcium channel blockers to β-adrenoceptor blockade for patients with exercise angina: a comparison of different compounds, 468P
SCHIFFELERS, S.L.H., SARIS, W.H.M. & VAN BAAK NUTRIM, M. A. β_1- and β_2-adrenergic receptor stimulation of thermogenesis and lipid utilizationin obese and lean men, 469P
SCHILLEVOORT, I.E.R.M., HERINGS, R.M.C., KUTIKOVA, L., HUGENHOLTZ, G.W.K., ROOS, R.A.C. & LEUFKENS, H.G.M. Drug-induced parkinsonism in psychiatric patients; a case-control study, 475P
SCHMETTERER, L. *see* MAYER, B.X.
SCHNEIDER, H.T. *see* TEGEDER, I.
SCHNEIDER, P. *see* RITZ, M.A.
SCHOEMAKER, H.C. *see* BURGGRAAF, J.
SCHOEMAKER, R.C. *see* FAAIJ, R.A.
SCHOOK, C.E. *see* VAN DEN ENDE, R.
SCHULTZ, M.J. *see* GUCHELAAR, H.-J.
SCHULZ, R. *see* WEBER, C.
SCHUMACHER, H. *see* SCHÄFERS, R.F.
SCOTT, K. *see* FEELY, J.
SEIDELL, J.C. *see* KLUNGEL, O.H.
SEINO, Y. *see* FUJITA, J.
SEKIYA, S. *see* NAKAMURA, H.
SEYMOUR, R.A., HAWKESFORD, J.E., HILL, C.M., FRAME, J. & ANDREWS, C. The efficacy of a novel adenosine agonist (WAG 994) in postoperative dental pain, 675
SHAW, D., MURRAY, V. & VOLANS, G. Adverse effects of herbal remedies and OTC medicines, 227
SHENFIELD, G.M. *see* GROSS, A.S.
SHERIDAN, D.J., KINGSBURY, M.P. & FLORES, N.A. Regression of left ventricular hypertrophy; what are appropriate therapeutic objectives?, 125
SHIELS, P. *see* MACFADYEN, R.J.
SHIELS, P., LIM, P.O., LEARY, A.C., MCMAHON, A.D. & MACDONALD, T.M. Angiotensin II receptor subtype I antagonism and diastolic cardiac filling in man, 337
SICA, L. *see* PANSERAT, S.
SILKE, B. *see* HANRATTY, C.G.
SIM, E. *see* RIDHA, B.
SINISALO, J., VANHANEN, H., PAJUNEN, P., VAPAATALO, H. & NIEMINEN, M.S. Ursodeoxycholic

acid and endothelial-dependent, nitric oxide-independent vasodilatation of forearm resistance arteries in patients with coronary heart disease, 661
SINNOTT, M.M. *see* WEN, Y.
SMITH, J.M. *see* CAMPBELL, M.
SMITH, P.J.W., FERRO, C.J., MCQUEEN, D.S. & WEBB, D.J. Impaired cholinergic dilator response of resistance arteries isolated from patients with Raynaud's disease, 507
SOHTELL, L. *see* ERICSSON, H.
SOMERS, G. *see* LEE, Y.
SOMOGYI, A.A. *see* FOSTER, D.J.R.
SOONS, P.A. *see* ROON, K.I.
SORENSEN, H.T. *see* OLESEN, C.
SPARIDANS, R.W. *see* CREMERS, S.C.L.M.
SPRATT, J.C.S., GODDARD, J., LABINJOH, C., STRACHAN, F.E., PATEL, N., RANKIN, A.J. & WEBB, D.J. The haemodynamic effects of systemic endothelin A receptor antagonism in healthy humans *in vivo*, 576P
SRIVASTAVA, N. *see* FAAIJ, R.A.
STAMATELOPOULOS, S. *see* ILIOPOULOU, A.
STEFFENSEN, F.H. *see* OLESEN, C.
STEINER, J. Self-assembling delivery complexes for gene delivery, from laboratory to clinical trial, 709
STEPANAVAGE, M.E. *see* LEE, Y.
STEVENS, L.A. *see* HOUSTON, A.C.
STOCCHI, F. *see* TAYLOR, A.
STRACHAN, F.E. *see* SPRATT, J.C.S.
STRICKER, BH.CH. *see* KLUNGEL, O.H.
STROBEL, W. *see* SCHÄCHINGER, H.
STRUIJKER, H.A.J. *see* DE HOON, J.N.J.M
STRUTHERS, A.D. *see* MACFADYEN, R.J.
STRUTHERS, A.D. Why does spironolactone improve mortality over and above an ACE inhibitor in chronic heart failure?, 479
SUGIMOTO, K.-I. *see* HARADA, K.
SULTAN, E. *see* PATAT, A.
SUNZEL, M. *see* ERICSSON, H.
SWAN, L., HOOD, S., BIRNIE, D.H., MUIR, D.F., MCCANN, G.P. & HILLIS, W.S. The haemodynamic effect of the $5HT_1$ agonist BMS-180048: a class effect of triptans?, 189
SWAN, S.K. *see* ANJUM, S.
SZABADI, E. *see* TAVERNOR, S.J.

TAGUCHI, K. *see* SCHÄFERS, R.F.
TAKADA, K. *see* FUKUDA, T.
TAKAHASHI, K. *see* KOBAYASHI, J.
TAKEDA, T. *see* FUJITA, J.
TAMMINGA, W.J., WEMER, J., OOSTERHUIS, B., WIELING, J., WILFFERT, B., DE ZEEUW, R.A., DE LEIJ, L.F.M.H. & JONKMAN, J.H.G. Evidence for gender differences on CYP2C19 activity in Dutch healthy volunteers in clinical pharmacology studies, 472P
TAN, C.H. *see* LEE, H.S.
TANAKA, M. *see* TATEISHI, T.
TANG, C. *see* PRUEKSARITANONT, T.
TANGPHAO, O., GROSSMANN, M., CHALON, S., HOFFMAN, B.B. & BLASCHKE, T.F. Pharmacokinetics of intravenous and oral L-arginine in normal volunteers, 261
TATEISHI, T., KUMAI, T., WATANABE, M., NAKURA, H., TANAKA, M. & KOBAYASHI, S. Ticlopidine decreases the *in vivo* activity of CYP2C19 as measured by omeprazole metabolism, 454
TAVERNOR, S.J., ABDULJAWAD, K.A.J., LANGLEY, R.W., BRADSHAW, C.M. & SZABADI, E. Effect of pentagastrin on the pupil and cardiovascular functions in healthy volunteers, 582P
TAYLOR, A., BEERAHEE, A., CITERONE, D., DAVY, M., FITZPATRICK, K., LOPEZ-GIL, A. & STOCCHI, F. The effect of steady-state ropinirole on plasma concentrations of digoxin in patients with Parkinson's disease, 219
TEGEDER, I., LEVY, M., MUTH-SELBACH, U., OELKERS, R., NEUMANN, F., DORMANN, H., AZAZ-LIVSHITS, T., CRIEGEE-RIECK, M., SCHNEIDER, H.T., HAHN, E.-G., BRUNE, K. & GEISSLINGER, G. Retrospective analysis of the frequency and recognition of adverse drug reactions by means of automatically recorded laboratory signals, 557
TEISMAN, A.C.H., VAN VELDHUISEN, D.J., DE KAM, P.J., BOOMSMA, F., TJEERDSMA, G., PINTO, Y.M., DE ZEEUW, D. & VAN GILST, W. H. Neurohormonal profile of patients with moderate to severe heart failure treated chronically with -adrenoceptor blockers, 469P
TEITELBAUM, P. *see* JUNG, D.
TEJURA, B. *see* CHALON, S.
TELLINGEN, O.V. *see* MEERUM TER WOGT, J.M.
TEN BOKKEL HUININK, W.W. *see* MEERUM TER WOGT, J.M.
TENNEZÉ, L., DAURAT, V., TIBI, A., CHAUMET-RIFFAUD, P. & FUNCK-BRENTANO, C. A study of the relative bioavailability of cysteamine hydrochloride, cysteamine bitartrate and phosphocysteamine in healthy adult male volunteers, 49
TER HOFSTEDE, H.J.M., BRINKMAN, K., KOOPMANS, P.P., HUGEN, P.W.H. & BURGER, D.M. Lactate/pyruvate elevation after oral glucose as a possible marker for mitochondrial toxicity in antiretroviral drugs, 475P
TER HOFSTEDE, H.J.M., VAN DER VEN, A.J.A.M. & KOOPMANS, P.P. Drug reactions to cotrimoxazole in HIV infection: possibly not due to the hydroxylamine metabolites of sulphamethoxazole, 571
THOMAS, S.H.L. *see* CAMPBELL, M.
THOMAS, S.H.L. *see* YEATES, P.J.A.
THOMAS, T.H. *see* JEENAPONGSA, R.
THORSSON, L., BORGÅ, O. & EDSBÄCKER, S. Systemic availability of budesonide after nasal administration of three different formulations, pressurized aerosol, aqueous pump spray, and powder, 619
TIBBEN, M.M. *see* HUITEMA, A.D.R.
TIBI, A. *see* TENNEZÉ, L.
TIMM, U. *see* WITTKE, B.
TJADEN, U.R. *see* VAN DER HEYDEN, S.A.M.
TJEERDSMA, G. *see* TEISMAN, A.C.H.
TRACY, T.S., KORZEKWA, K.R., GONZALEZ, F.J. & WAINER, I. W. Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil, 545
TSUBO, T. *see* HIROTA, K.
TSUDA, K. *see* FUJITA, J.
TUCKER, G.T. *see* ABDUL-MANAP, R.
TUCKER, G.T. *see* FORSYTH, J.
TUCKER, G.T. *see* GHAHRAMANI P.
TUCKER, G.T. *see* ROSTAMI-HODJEGAN, A.
TUCKER, G.T., BACK, D. & MCINNES, G. Green into silver, 1

UEHLINGER D.E. *see* PFISTER, M.
UITENDAAL, M.P. *see* ROON, K.I.
URAE, A. *see* CHALON, S.
URAE, A. *see* KIMURA, M.

VALLANO, A., AGUILERA, C., ARNAU, J.M., BAÑOS, J.-E. & LAPORTE, J.-R., Management of postoperative pain in abdominal surgery in Spain. A muticentre drug utilization study, 667
VAN AGTMAEL, M.A., GUPTA, V. & VAN BOXTEL, C.J. Grapefruit juice increases bioavailability of artemether without an effect on the time-dependent autoinduction, 467P
VAN BAAK NUTRIM, M.A. *see* SCHIFFELERS, S.L.H.

VAN BORTEL, L.M.A.B. *see* DE HOON, J.N.J.M
VAN BOXTEL, C.J. *see* VAN AGTMAEL, M.A.
VAN DE VIJVER, DE BOER, A., HERINGS, R.M.C., ROOS, R.A.C. & PORSIUS, A.J. Increased use of pscyhotropic drugs by patients with Parkinson's disease, 476P
VAN DEN ENDE, R., BOEIJINGA, J.K., VAN MEEGEN, E., SCHOOK, C.E. & COHEN, A.F. Lack of interaction between tramadol and coumarins, 466P
VAN DER HEYDEN, S.A.M., HIGHLEY, M.S., DE BRUIJN, E.A., TJADEN, U.R., REEUWIJK, H.J.E.M., VAN SLOOTEN, H., VAN OOSTEROM, A.T. & MAES, R.A.A. Pharmacokinetics and bioavailability of oral 5′-deoxy-5-fluorouridine in cancer patients, 351
VAN DER MERBEL, N. *see* VAN LIER, J.J.
VAN DER POLL, T. *see* GUCHELAAR, H.-J.
VAN DER VEN, A.J.A.M. *see* TER HOFSTEDE, H.J.M.
VAN DER VRING, J.A.F.M., DANIELS, M.C.G., HOLWERDA, N. J.H., WITHAGEN, P.J.A.M., SCHELLING, A., CLEOPHAS, T.J. & HENDRIKS, M.G.C. Combination of calcium channel blockers and β-adrenoceptor blockers for patients with exercise-induced angina pectoris: a double-blind parallel-group comparison of different classes of calcium channel blockers, 493
VAN DER VRING, J.A., DANIELS, M.C., HOLWERDA, N.J., WITHAGEN, P.J., SCHELLING, A., CLEOPHAS, T.J., HENDRIKS, M.G. on behalf of the Netherlands Working Group on Cardiovascular Research (WCN). Addition of calcium channel blockers to β-adrenoceptor blockade for patients with exercise angina: a comparison of different compounds, 468P
VAN DER WERF, G.TH. *see* WIERINGA, N.F.
VAN GILST, W.H. *see* TEISMAN, A.C.H.
VAN GRIENSVEN, J.M.TH. *see* FAAIJ, R.A.
VAN HAARST, A.D. *see* BURGGRAAF, J.
VAN HEESWIJK, R.P.G., VELDKAMP, A.I., WIT, F.W.N.M., HOETELMANS, R.M.W., MEENHORST, P.L., MULDER, J.W., LANGE, J.M.A., REISS, P. & BEIJNEN, J.H. Is the exposure to nevirapine (Viramune) equivalent in a dosage of 400 mg once daily and 200 mg twice daily, 464P
VAN LIER, J.J., PEETERS, P.A.M., VAN VLIET, A.A., WEMER, J., VAN DER MERBEL, N., OOSTERHUIS, B., WIELING, J., KLESSING, K., BIBER, A. & JONKMAN, J.H.G. Excretion balance, pharmacokinetic and metabolism study after single oral doses of [^{14}C] labelled losigamone and both enantiomers in healthy male volunteers, 472P
VAN MEEGEN, E. *see* VAN DEN ENDE, R.
VAN OOSTEROM, A.T. *see* VAN DER HEYDEN, S.A.M. VAN PUIJENBROEK, E.P., EGBERTS, A.C.G., MEYBOOM, R.H. B. & LEUFKENS, H.G.M. Signalling possible drug–drug interactions in a spontaneous reporting system, delay of withdrawal bleeding during concomitant use of oral contraceptives and itraconazole, 689
VAN SLOOTEN, H. *see* VAN DER HEYDEN, S.A.M.
VAN VELDHUISEN, D.J. *see* TEISMAN, A.C.H.
VAN VLIET, A.A. *see* VAN LIER, J.J.
VANAKOSKI, J. *see* MATTILA, M.J.
VANHANEN, H. *see* SINISALO, J.
VAPAATALO, H. *see* SINISALO, J.
VARANI, K., GESSI, S., CAIAZZA, A., RASTELLI, G., PORTALUPPI, F. & BOREA, P.A. Platelet α_2-adrenoceptor alterations in patients with essential hypertension, 167
VEENHOF, C.H.N. *see* MEERUM TER WOGT, J.M.
VELDKAMP, A.I. *see* VAN HEESWIJK, R.P.G.
VERMEIJ, P. *see* CREMERS, S.C.L.M.
VILAR, F.J., KHOO, S.H.& WALLEY, T. The management of *Pneumocystis carinii* pneumonia, 605
VILLANI, P. *see* REGAZZI, M.B.
VOLANS, G. *see* SHAW, D.
VOORTMAN, H.-J. *see* KNIBBE, C.A.J.
VORA, A. *see* FAUSET, A.
VOS, R. *see* WIERINGA, N.F.

WADA, Y. *see* KIMURA, M.
WAINER, I.W. *see* TRACY, T.S.
WALLER, P. Improving the regulatory review process, 713
WALLEY, T. *see* VILAR, F.J.
WALLIS, E.J. *see* HAQ, I.U.
WALLIS, E.J. *see* NICHOLSON, K.
WALLIS, E.J., YEO, W.W., JACKSON, P.R. & RAMSAY, L.E. Effect on ACE inhibitor cough of replacing the ACE inhibitor with losartan, 598P
WARRANDER, A. *see* MINTON, N.
WASMUTH, A. *see* SCHÄFERS, R.F.
WATANABE, M. *see* TATEISHI, T.
WEBB, D.J. *see* SMITH, P.J.W.
WEBB, D.J. *see* SPRATT, J.C.S.
WEBB, J., MIKUS, G., HOFMANN, U. & KAMALI, F. Assessment of the relationship between analgesia and plasma concentrations of dihydrocodeine and dihydromorphine following dihydrocodeine administration, 583P
WEBER, C., BANKEN, L., BIRNBOECK, H., NAVE, S. & SCHULZ, R. The effect of bosentan on the pharmacokinetics of digoxin in healthy male subjects, 701
WEMER, J. *see* TAMMINGA, W.J.
WEMER, J. *see* VAN LIER, J.J.
WEN, Y., DOYLE, M.C.T., NORRIS, L.A., SINNOTT, M.M., COOKE, T., HARRISON, R.F. & FEELY, J. Combined oestrogen–progestogen replacement therapy does not inhibit low-density lipoprotein oxidation in postmenopausal women, 315
WHITE, I.N.H. *see* BOOCOCK, D.J.
WIELING, J. *see* TAMMINGA, W.J.
WIELING, J. *see* VAN LIER, J.J.
WIERINGA, N.F., DE GRAEFF, P.A., VAN DER WERF, G. TH. & VOS, R. Discrepancies between clinical trial populations and post-registration use: a focus on hypertension, 477P
WILD, M. *see* MINTON, N.
WILFFERT, B. *see* TAMMINGA, W.J.
WILKINSON, G.R. *see* KINIRONS, M.T.
WILKINSON, T.J., BEGG, E.J., WINTER, A.C. & SAINSBURY, R. Incidence and risk factors for hyponatraemia following treatment with fluoxetine or paroxetine in elderly people, 211
WILLIAMS, D. *see* FEELY, J.
WILLIAMS, D., KELLY, A. & FEELY, J. Drug interactions avoided: an index of good prescribing practice, 595P
WILLIAMS, D., KELLY, A. & FEELY, J. Effect of the Committee on Safety in Medicines (CSM) warning on contraceptive use in the general medical services (GMS) in Ireland, 580P
WILLIAMS, S.M. *see* BEGGS, P.W.
WILSON, G. *see* FAUSET, A.
WINGEN, A.-M. *see* R.BUSCHER
WINTER, A.C. *see* WILKINSON, T.J.
WIT, F.W.N.M. *see* VAN HEESWIJK, R.P.G.
WITHAGEN, P.J.A.M. *see* VAN DER VRING, J.A.F.M.
WITHAGEN, P.J. *see* VAN DER VRING, J.A.

WITTKE, B., MACKIE, I.J., MACHIN, S.J., TIMM, U., ZELL, M. & GOGGIN, T. Pharmacokinetics and pharmacodynamics of Ro 44–3888 after single ascending oral doses of sibrafiban, an oral platelet aggregation inhibitor, in healthy male volunteers, 521
WOLZT, M. *see* MAYER, B.X.
WONG, K.E. *see* LEE, H.S.
WOOD, A.J.J. *see* KINIRONS, M.T.
WRIGHT, C.E. *see* ABDUL-MANAP, R.
WRIGHT, D.J. *see* HAWKSWORTH, G.M.

YAMAGATA, S.-I. *see* NAKAMURA, H.
YAMAMOTO, I. *see* FUKUDA, T.
YAMAZAKI, S. *see* HARADA, K.
YAP, H.L. *see* LEE, H.S.
YEATES, P.J.A. & THOMAS, S.H.L. Effect of delayed activated charcoal administration on paracetamol absorption after simulated overdose, 599P
YEO, W.W. *see* HAQ, I.U.
YEO, W.W. *see* NICHOLSON, K.
YEO, W.W. *see* ROWLAND, K.
YEO, W.W. *see* WALLIS, E.J.
YOUNG, P.I. *see* CAMPBELL, M.
YU, L. *see* FUJITA, J.

ZELL, M. *see* WITTKE, B.
ZHANG, Y.D. *see* CAI, W.M.
ZHOU, Q. *see* FUKUDA, T.
ZIEL, A. *see* RITZ, M.A.

© 1999 Blackwell Science Ltd

SUBJECT INDEX

This index was compiled from the keywords

α-adrenoceptors, 427
α_1-adrenoceptor, 67
β-adrenoceptor blocker, 493
β-adrenoceptor blocking drugs, 468P, 469P
β-adrenoceptors, 59, 157, 173, 427
Absolute neutrophil count, 279
Absorption, 273
ACE inhibitor, 479, 598P
Acenocoumarol, 225, 441
Acetylator status, 592P
Acetylcysteine, 581P
Acoustic startle reflex, 421
Actigraphy, 601P
Acute otitis media, 267
Adenosine agonist, 675
Adenylate cyclase signalling, 594P
Adenylyl cyclase, 576P
Administration oral, 351
Adults, 273
Adverse drug reactions, 228, 557, 681
Adverse effects, 227
Adverse event, 49
Aetiologies, 239
Ageing, 83, 594P
Alcohol, 582P, 600P
Alniditan, 285
Alpha interferon, 365
Anaesthetic agents, 35
Anaesthetics i.v., 653
Analgesia, 583P
Analgesics, 667
Angina pectoris, 493
Angina, 468P
Angiotensin converting enzyme genotypes, 471P
Angiotensin converting enzyme inhibitors, 111, 469P
Angiotensin I, 471P
Angiotensin II receptor antagonism, 111, 337
Angiotensin II receptor blockade, 586P
Angiotensin II, 471P
Angiotensin-converting enzyme inhibitors, 179
Anniversary commentaries, 1, 3, 5, 7, 11
Antihistamines, 307
Antihyperlipidaemic agents, 99
Antimetabolites, 131
Antimicrobial agents, 23
Antimuscarinic, 145
Antioxidant, 315
Antipsychotics, 475P
Antiretroviral drugs, 475P
Artemether, 467P
Arterial stiffness, 575P
Artificial neural networks, 589P
Asthma, 357
Atherosclerosis, 315
Autoinduction, 467P
Automated laboratory signals, 557
Azithromycin penetration, 267

Bantu population, 121
Beclamethasone 474P
Behavioural problems, 601P
Benzodiazepine, 421
Bezafibrate, 99
Bioavailability, 351, 467P, 473P
Bioequivalence, 49
Blood pressure reduction, 531
BMS-180048, 189
Budesonide, 619

Ca^{2+}-channel blocker, 499
Caco-2 cells, 594P
Caffeine, 579P
Caffeine test, 445
Calcium antagonist, 531
Calcium channel blockers, 468P, 493
cAMP, 167
Cancer, 463P
Candesartan cilexetil, 645
Carboplatin, 463P
Cardiac hypertrophy, 125
Cardiac repolarization, 515
Cardiac surgery, 531
Cardiovascular function, 582P
Case studies, 239
Cefixime, 267
Ceftibuten, 267
Cellular uptake, 383
Cerebrovascular disease, 476P
Charcoal, 599P, 613
Children, 333
Chinese, 151, 553
Chiral inversion, 391
Cholecystokinin, 582P
Chronopharmacology, 413
Clevidipine, 531
Clinical applicability, 115
Clinical cardiac failure, 239
Clinical pharmacology, 611
Clinical pharmacy, 231, 695
Clinical trial populations, 477P
Committee on Safety of Medicines, 580P
Community pharmacists, 695
Contraceptive use, 580P
Cooling, 507
Coronary haemodynamics, 125
Coronary heart disease, 597P, 661
Cotrimoxazole, 571
Cough, 111, 598P
Coumarins, 466P
Cremophor EL, 463P
CVA, 565
Cyclophosphamide, 465P
Cyclosporin, 463P, 589P
Cyctochrome P450 1A2, 445
CYP1A2 activity, 397, 587P
CYP1A2, 145, 299, 445
CYP2C19, 115, 145, 454, 472P
CYP2C9, 625
CYP2D6 activity, 577P
CYP2D6 polymorphism, 121
CYP2D6*10 genotype, 450
CYP2D6, 145, 553, 586P
CYP2E1, 299
CYP3A, 31, 291, 454
CYP3A4, 145, 403, 593P, 598P
Cysteamine salts, 49
Cysteamine, 49
Cystinosis, 49
Cytochrome P450, 299, 545
Cytosine arabinoside, 131
Cytoskeleton, 594P
Cytotoxic drugs, 131

Dapsone recovery ratio, 223
Debrisoquine, 591P
Decision-making, 329
Dental surgery, 391
Desensitization, 59
Desmethylselegiline, 249
Dexfenfluramine, 565
Dextromethorphan, 586P
Diabetes mellitus, 427
Diagnosis, 239
Diastolic cardiac filling, 337
Diastolic failure, 239
Diazepam, 600P
Dietary caffeine, 397
Digoxin, 219, 701
Dihydrocodeine, 583P
Dihydroergotamine, 470P
Dihydromorphine, 583P
Diltiazem, 598P
Dispensing, 695
Doctors, 582P
Dopamine, 471P
Dosage errors, 581P
Doxifluridine, 351
Driving, 600P
Drug administration — inhalation, 357
Drug development, 5
Drug discovery, 5
Drug hypersensitivity, 596P
Drug interaction, 255
Drug interactions, 291, 454, 689
Drug regulation, 11
Drug therapy, 7
Drug use evaluation, 667
Drug use, 323
Drug utilization studies, 667
Drug–drug-interactioin, 701
Drugs, 329
Dutasteride, 53
Dysrhythmia, 239

© 1999 Blackwell Science Ltd

EDDP formation, 403
Elderly, 211, 600P, 601P
Electrophysiology, 125
Electrostatic charge, 333
Emulsion formulation, 653
Enantiomers, 472P, 545, 553
Endothelin A receptor antagonism, 576P
Endothelin antagonists, 701
Endothelium, 91, 507, 661
Enzyme induction, 445
Epilepsy, 472P
Erythrocyte deformability, 499
Erythromycin breath test, 223
Erythromycin, 466P
Ethanol, 591P
Extracellular fluid space, 361

Female sex steroids, 249
Fluconazole, 707
Flumazenil, 421
Fluorouracil, 131, 351
Fluoxetine, 211
Flutamide, 43
Fluvastatin, 383
Forearm, 173
Formulation, 474P
Fosinopril, 179

G proteins, 167
Ganciclovir, 255
Gemfibrozil, 99
Gender differences, 472P
Gene polymorphism, 445
Genotype, 115, 121, 592P, 597P
Gentamicin, 637
Glomerulonephritis, 203
Glucose, 361
Glucuronylation, 578P
Good prescribing practice, 595P
Granulocyte colony-stimulating factor, 279
Grapefruit juice, 467P, 593P
Growth hormone deficiency, 273
Growth hormone, 273
GTN, 173
Gut hormone, 195

H_1-receptor antagonist, 515
Haemodialysis, 576P, 645
Haemodialysis patients, 365
Haemodynamic effects, 59, 189
Hallucinations, 226
Hashimoto's thyroiditis, 592P
Healthy volunteers, 279, 472P, 515
Heart failure, 469P, 479
Heart rate variability, 157
Herbal remedies, 227
HIV infection, 379, 571, 605
HMG-CoA reductase inhibitor, 291, 383
Hormone replacement therapy, 315, 323
Hospital records, 596P
Hospital, 667
Hospitalized children, 681
Human aortic endothelial cells, 383
Human genome, 7
Human liver microsomes, 403
Human microsomes, 625
Human middle meningeal artery, 75
Human platelets, 167
Human veins, 83
Human, 507
Hydrofluoroalkane, 333
6β-hydroxycortisol, 31
α-hydroxytamoxifen, 578P
5-HT, 189
5-$HT_{1B/1D}$ receptor agonist, 285
5-HT_4 receptor agonist, 483
5-HT-receptor subtypes, 75
Hypertension, 179, 476P, 477P, 573, 586P, 645
Hyponatraemia, 211

Ibuprofen enantiomers, 391
Ibuprofen, 675
Ileostomy, 474P
Illicit drug use, 582P
Immunosuppressant drugs, 339
In vitro metabolism, 291
In vitro predictions, 625
Incidence, 323
Induction characteristics, 653
Induction, 653
Inhalation, 613
Insulin, 433
Interaction, 225, 249, 441, 466P, 588P, 595P, 707
Interleukin-6, 466P
Interventions, 695
Intracellular free calcium ion, 499
Intravenous, 261
Intrinsic clearance, 625
Isoniazid, 591P
Isoprenaline, 91
Itraconazole, 689

Ketoconazole, 223
Ketoprofen, 459
Ketotifen, 59

Labetalol, 573
Laboratory pharmacology, 611
Lactate/pyruvate ratio, 475P
L-arginine, 261, 539
LDL oxidation, 315
Left ventricular hypertrophy, 179
Lenograstim, 279
Light and dark conditions, 600P
Limited sampling strategy, 365
Linear regression, 589P
Lipoprotein lipase, 433
Liver function, 590P
L-NMMA, 539
Losartan, 111, 598P
Losigamone, 472P
Lung cancer, 463P
Lung delivery, 333

Management issues, 239
Medical students, 582P
Membranous glomerulonephritis, 203
MEMO, 105
Mercaptopurine, 131
Metabolic ratio, 397
Metabolism, 545
Methadone *N*-demethylation, 403
Methotrexate, 131
Mibefradil, 291
Miconazole, 225
Midazolam, 421
Middle ear fluid, 267
Migraine, 189, 285, 373, 588P
Milameline, 590P
Minimal change nephropathy, 203
Mitochondrial toxicity, 475P
Mizolastine, 515
Modelling, 464P, 466P, 483, 578P
Monoamine oxidase B inhibitor, 584P
Mortality, 479
Mothers, 31
Multispecific anion transporter, 383
Myocardial infarction, 580P

Nabumetone, 441
Nasal spray, 285
Nasal, 619
Neonates, 31, 459
Nephrotic syndrome, 203
Neuroendocrine tumour, 195
Nevirapine, 464P
NIDDM, 499
Nifedipine, 707
Nisoldipine, 499
Nitric oxide synthesis, 539
Nitric oxide, 91, 173, 507
Nitroglycerin, 427
Nonlinear, 53, 157
NONMEM, 53, 465P, 645
Non-steroidal antiinflammatory drugs, 203
Normal clinical practice, 99
Norverapamil, 545
NPY receptors, 83
NSAID nephropathy, 203

Octastatin, 195
Oestrogen, 315, 323, 589P
Omeprazole hydroxylation index, 111
Omeprazole, 454
Onset of analgesia, 391
Optimal treatment, 239
Oral contraceptives, 689
Oral platelet inhibitor, 521
Oral, 261
Over the counter medicines, 227
Overactive bladder, 145
Overdose, 599P

Paclitaxel, 463P
Paediatric patients, 681
Pain relief, 391
Pamidronate, 464P
Paracetamol, 599P
Paraxanthine/caffeine ratio, 587P
Parkinson's disease, 219, 476P, 579P
Parkinsonism, 475P
Paroxetine, 211
Partial agonist, 157

© 1999 Blackwell Science Ltd

Parturition, 573
Passive smoking, 575P
Pentagastrin, 582P
Pentosan polysulphate sodium, 473P
Pentosan, 473P
P-glycoprotein, 593P, 594P
Pharmacodynamics, 466P, 521, 539, 584P
Pharmacoepidemiology, 329
Pharmacogenetics, 597P
Pharmacokinetics, 35, 43, 49, 53, 151, 219, 249, 261, 279, 285, 351, 361, 373, 379, 450, 463P, 464P, 465P, 466P, 472P, 483, 521, 531, 539, 553, 590P, 591P, 619, 637, 653, 701
Pharmacology, 653
Pharmacovigilance, 105, 329, 689
Phase I clinical trials, 351
Phenotype, 115, 121, 553, 592P, 597P
Phenotyping, 397
Phentermine, 565
Phosphocysteamine, 49
Pneumocystis carinii, 605
Pneumonia, 605
Polymorphism, 145
Population pharmacokinetics, 365, 531
Postmarketing surveillance, 99
Postmenopause, 315
Postoperative pain, 667, 675
Post-registration use, 477P
Pregnancy, 573
Prepulse inhibition, 421
Prescription-event monitoring, 111
Presystemic metabolism, 413
Prevalence, 323
Propafenone, 553
Propofol, 35, 653
Protein binding, 35
Psychiatric patients, 475P
Psychotropic drugs, 476P
Pupil, 582P

Radiocontrast media, 226
Rat primary cultured hepatocytes, 383
Raynaud's disease, 507
Receptor agonist, 189
Record-linkage, 105
5α-reductase inhibitor, 53
Regression, 125
Relative lung bioavailability, 613
Renal failure, 43, 459
Renal function, 637
Renal impairment, 577P
Resistance arteries, 507
rHuG-CSF, 279
Risk factors, 211
Risperidone, 460
Ritodrine, 173
Rizatriptan, 373
Ro 44-3888, 521
Ropinirole, 219

Safety, 584P
Salbutamol, 333
Saquinavir, 379, 593P, 594P
Scatterplot, 157
Schizophrenia antipsychotics, 13
Schizophrenia, 460
SDZ HTF 919, 483
Selegiline, 249
Septic patients, 471P
Serotonin, 173
Sibrafiban, 521
Side effects, 203
Signal detection, 689
Simvastatin, 99, 597P, 598P
SL34.0026, 584P
Sleep, 601P
Sodium cromoglycate, 613
Sodium nitroprusside, 91
Somatotropin, 273
Spacer devices, 357
Spironolactone, 479
Spontaneous reporting, 329
Stable isotope technique, 413
Statins, 291
Step-3 diet, 597P
Stereoisomers, 573
Stereoselectivity, 403
Subcutaneous infusion, 195
Substrate selectivity, 299
Sulphamethoxazole, 571
Systemic availability, 619
Systolic failure, 239
Systolic time intervals, 59

3T3-L1 cells, 433
Tamoxifen, 578P
Tamsulosin, 67
Taxol, 463P
Terazosin, 67
Theobromine, 299
Therapeutic drug monitoring, 23, 131, 339
Therapeutic intensity, 323
Thiopurine methyltransferase, 597P
Third molar surgery, 675
Ticlopidine, 454
Tolbutamide, 151
Tolterodine, 145
Tramadol, 466P, 591P
Transmembrane signal transduction, 594P
Treatment outcomes, 99
Trial evidence, 239
Trimethoprim, 255
Troglitazone, 433
Tubulointerstitial nephritis, 203
Tumour necrosis factor, 466P

[^{3}H]-UK 14304 binding, 167
Ultrashort-acting, 531
Upper gastrointestinal bleeding, 195
Urinary excretion, 613
Urine, 31
Ursodeoxycholic acid, 661

Validation, 397
Valsartan, 337
Vascular response, 427
Vascular stiffness, 586P
Vasoconstriction, 67, 75
Vein, 91
Venlafaxine, 450
Venoconstriction, 83
Ventricular arrhythmias, 307
Verapamil, 413, 545
Vitamin E, 315
Vitamin K, 585P

Warfarin, 585P
Weibull function, 483
Withdrawal bleeding, 689

Xamoterol, 59
Xenoestrogens, 589P

Zolmitriptan, 588P